Comments to FDA: Developing Nicotine Replacement Therapy Drug Products Share page: Docket Number: FDA-2019-D-0297 CHPA welcomes the opportunity to comment on the draft guidance on indications for nicotine replacement therapies (NRT). Download Document Issues: OTC Medicines Rx-to-OTC Switch Other Issues Research Related Posts Press Releases and Statements Rates for Teen Abuse of OTC Cough/Cold Medication Remains Low According to NIDA Survey Dec 18, 2024 Pediatric Cough/Cold Dosing Press Releases and Statements CHPA Joins U.S. Senators Grassley & Coons at Anti-Counterfeiting Event Dec 13, 2024